Clinical trial
Combination Chemotherapy in Treating Patients With Stage II Bladder Cancer
NCT00002919 · Memorial Sloan Kettering Cancer Center, Other · Completed
Key facts
| NCT number | NCT00002919 |
|---|---|
| Title | Combination Chemotherapy in Treating Patients With Stage II Bladder Cancer |
| Official title | PHASE II TRIAL OF THE COMBINATION OF TRANSURETHRAL RESECTION AND NEOADJUVANT CHEMOTHERAPY FOR PATIENTS WITH INVASIVE UROTHELIAL TRACT TUMORS SELECTED BY STAGE AND P53 NUCLEAR EXPRESSION |
| Lead sponsor | Memorial Sloan Kettering Cancer Center, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Bladder Cancer |
| Intervention type | Biological, Drug, Procedure |
| Interventions | filgrastim, cisplatin, doxorubicin hydrochloride, methotrexate, vinblastine sulfate, conventional surgery |
| Enrollment | 30 |
| Start date | Nov 1, 1996 |
| Primary completion | Jan 1, 2003 |
| Completion | Jan 1, 2003 |
| First posted | Mar 12, 2004 |
| Last update posted | Jul 3, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: